Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14278787 | 1.00 | SRC (0.48) | SRCKMT2AMEN1SMN1; SMN2MTNR1A | |
| SCHEMBL4799364 | 1.00 | SRC (0.48) | SRCKMT2AMEN1SMN1; SMN2MTNR1A | |
| SCHEMBL4800666 | 0.84 | POLB (0.49) | KMT2AMEN1CYP2D6POLBLMNA | |
| SCHEMBL1883301 | 0.84 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL1883304 | 0.84 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL19625534 | 0.83 | CA1 (0.52) | SRCKMT2AMEN1SMN1; SMN2MTNR1A | |
| SCHEMBL2331132 | 0.83 | MME (0.51) | SRCKMT2AMEN1SMN1; SMN2MTNR1A | |
| SCHEMBL2329884 | 0.83 | MME (0.51) | SRCKMT2AMEN1SMN1; SMN2MTNR1A | |
| SCHEMBL10346709 | 0.83 | CA1 (0.52) | SRCKMT2AMEN1SMN1; SMN2MTNR1A | |
| SCHEMBL10346708 | 0.83 | CA1 (0.52) | SRCKMT2AMEN1SMN1; SMN2MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4067370-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE RELATED COMPOUNDS | Yu, Chongxi (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-2165709-B1 | Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent | AMBRILIA BIOPHARMA INC (CA) | 2016-03-16 | — | — | EP | disclosed |
| US-9133157-B2 | HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-09-15 | — | — | US | disclosed |
| EP-1877091-B1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | TAIMED BIOLOG INC (TW) | 2015-03-25 | — | — | EP | disclosed |
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-10-09 | — | — | US | disclosed |
| US-8580995-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | TAIMED BIOLOGICS, INC. (TW) | 2013-11-12 | — | — | US | disclosed |
| EP-1575914-B1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | TAIMED BIOLOG INC (TW) | 2013-10-16 | — | — | EP | disclosed |
| US-8227450-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | AMBRILIA BIOPHARMA INC. (CA) | 2012-07-24 | — | — | US | disclosed |
| US-20120053139-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2012-03-01 | — | — | US | disclosed |
| US-8008297-B2 | (1-{5-[(4-amino-benzenesulfonyl)-isobutyl-amino]-6-phosphonooxy-hexacarbomoyl}-2,2-diphenyl-ethyl)-carbamic acid methyl ester; which upon cleavage of cleavable bond or unit generates HIV-1 aspartyl protease inhibitor; antiviral agent; good solubility, and bioavailability; HIV or HTLV infection | AMBRILIA BIOPHARMA INC. (CA) | 2011-08-30 | — | — | US | disclosed |
| US-7321055-B2 | Production method of optically active dephenylalanine compounds | AJINOMOTO CO., INC. (JP) | 2008-01-22 | — | — | US | disclosed |
| EP-1877091-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | Ambrilia Biopharma Inc. (CA) | 2008-01-16 | — | — | EP | disclosed |
| US-20070032658-A1 | Production method of optically active dephenylalanine compounds | AJINOMOTO CO., INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20060287316-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2006-12-21 | — | — | US | disclosed |
| WO-2006114001-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2006-11-02 | — | — | WO | disclosed |
| US-20060025592-A1 | Lysine based compounds | TAIMED BIOLOGICS, INC. (TW) | 2006-02-02 | — | — | US | disclosed |
| EP-1575914-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Procyon Biopharma Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056764-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2004-07-08 | — | — | WO | disclosed |
| US-6632816-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | PHARMACOR INC. (CA) | 2003-10-14 | — | — | US | disclosed |
| WO-1993015042-A1 | PROCESS FOR THE PREPARATION OF D(-) AND L(+)-3,3-DIPHENYLALANINE AND D(-) AND L(+)-SUBSTITUTED 3,3-DIPHENYLALANINES AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025592-A1 | Lysine based compounds | DOT1L, H1-2, H1-0 | SRC 1748/4885KMT2A 12/4885MEN1 2117/4885 |
| US-20060287316-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | SPINT2, PREP, F2RL1 | SRC 2437/4885KMT2A 1225/4885MEN1 3286/4885 |
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, PRSS3 | SRC 3317/4885KMT2A 2167/4885MEN1 3595/4885 |
| US-20120053139-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | SPINT2, PREP, F2RL1 | SRC 2437/4885KMT2A 1225/4885MEN1 3286/4885 |
| US-20070032658-A1 | Production method of optically active dephenylalanine compounds | TYR, PAH, DDC | SRC 3616/4885KMT2A 788/4885MEN1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.